Natera (NTRA) IPO Opens Up 23%

Today's IPO for Natera, Inc. (Nasdaq: NTRA) opened for trading at $22.10 after pricing 10,000,000 shares of its common stock at a price to the public of $18, the high end of the expected $17 to $18 range.

In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.

Morgan Stanley, Cowen and Company, and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Baird and Wedbush PacGrow are acting as co-managers for the offering.

:Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to help families diagnose and manage genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers. Tests include pre-implantation genetic screening and diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos during in vitro fertilization (IVF); miscarriage testing to rapidly analyze fetal chromosomes to understand the cause of a pregnancy loss; carrier screening tests to detect whether parents carry genetic variations that may result in disease in their child; and Panorama™, a safe, simple test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation.

You May Also Be Interested In

• Loar Holdings (LOAR) Announces 11M Share IPO at $24-$26/sh
• Games Global (GGL) Files for Proposed IPO
• Mobix Labs (MOBX) Files S-1